SCHEMBL19743086

SCHEMBL19743086

[c]1nc2cnc3[nH]ccc3c2[nH]1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCI P41743 3/20 0.41
AXL P30530 2/20 0.41
JAK1 P23458 10/20 0.39
JAK2 O60674 10/20 0.38
KDR P35968 4/20 0.38
AURKA O14965 3/20 0.38
PRKCA P17252 3/20 0.38
JAK3 P52333 2/20 0.38
HPGDS O60760 1/20 0.36
MAPK1 P28482 1/20 0.36
NUDT1 P36639 3/20 0.36
IKBKB O14920 1/20 0.33
CHUK O15111 1/20 0.33
DAPK3 O43293 1/20 0.33
PRKD3 O94806 1/20 0.33
MAP4K4 O95819 1/20 0.33
PAK4 O96013 1/20 0.33
CSF1R P07333 1/20 0.33
RET P07949 1/20 0.33
IGF1R P08069 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2223296 0.73 PRKCI (0.44) PRKCIAXLJAK1JAK2KDR
SCHEMBL3863519 0.71 KDM4E (0.42)
SCHEMBL1933750 0.70 PRKCI (0.42) PRKCIAXLJAK1JAK2KDR
SCHEMBL4352565 0.68 NUDT1 (0.47) PRKCIAXLJAK1JAK2KDR
SCHEMBL29588119 0.68 PRKCI (0.47) PRKCIAXLJAK1JAK2KDR
SCHEMBL1933010 0.68 DYRK1A (0.47) PRKCIAXLJAK1JAK2KDR
SCHEMBL12424590 0.68 PRKCI (0.47) PRKCIAXLJAK1JAK2KDR
SCHEMBL28735162 0.68 PRKCI (0.40) PRKCIAXLJAK1JAK2KDR
SCHEMBL2319296 0.67 PRKCI (0.42) PRKCIAXLJAK1JAK2KDR
SCHEMBL24457934 0.66 AXL (0.41) PRKCIAXLJAK1JAK2KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3702354-B1 COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF HAIHE BIOPHARMA CO LTD (CN) 2024-05-22 EP disclosed
EP-3750885-A1 COMPOUND HAVING BET INHIBITORY ACTIVITY AND PREPARATION METHOD AND USE THEREFOR Shanghai Haihe Pharmaceutical Co., Ltd. (CN) 2020-12-16 EP disclosed
EP-3702354-A1 COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF Shanghai Haihe Pharmaceutical Co., Ltd. (CN) 2020-09-02 EP disclosed
US-20200247781-A1 COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF HAIHE BIOPHARMA CO., LTD. (CN) 2020-08-06 US disclosed
WO-2019154329-A1 COMPOUND HAVING BET INHIBITORY ACTIVITY AND PREPARATION METHOD AND USE THEREFOR 上海海和药物研究开发有限公司 2019-08-15 WO disclosed
US-10131675-B2 Tricyclic DLK inhibitors and uses thereof GENENTECH, INC. (US) 2018-11-20 US disclosed
US-20170369510-A1 TRICYCLIC DLK INHIBITORS AND USES THEREOF GENENTECH, INC. (US) 2017-12-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10131675-B2 Tricyclic DLK inhibitors and uses thereof NLK, DCLK2, DLK1 PRKCI 473/4885AXL 3903/4885JAK1 638/4885
US-20200247781-A1 COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF MAPK1, MAPK4, MAPK7 PRKCI 529/4885AXL 613/4885JAK1 194/4885
US-20170369510-A1 TRICYCLIC DLK INHIBITORS AND USES THEREOF NLK, DCLK2, DLK1 PRKCI 473/4885AXL 3903/4885JAK1 638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.